Duke Performs First Treatments under EDAP Study Sponsorship

From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer UroToday.com announced today the addition of Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results

EDAP Announces Details on Termination Agreement With HealthTronics LYON, France, April 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production,

Company Reclaims Full US Market Rights; Ablatherm-HIFU Trial to Resume Immediately

Company Restarts US Trials for Localized Prostate Cancer HIFU

Longest HIFU Clinical Results Confirm Addition to Standard of Care Protocols; Symposium Confirms Ablatherm Strong Outcomes

Six-City Tour Generates Awareness, Training Demand for Ablatherm-HIFU TherapyEAU Congress Interest Advances German Market Growth

Distributor Meeting, User Group Sessions, Media Conferences to Highlight Ablatherm-HIFU

Mobile RPP Utilization Increasing, New Centers Added; Strong Commitment from Distribution Partne

Europe's RPP Program: On Track to Group Profitability The USA: EDAP's New and Exciting Opportunity